Several embodiments of the present disclosure relate to glycotargeting therapeutics that are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent. In several embodiments, the compositions are configured to target the liver and deliver antigens to which tolerance is desired. Methods and uses of the compositions for induction of immune tolerance are also disclosed herein.

Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.

The invention relates to intradermal administration of an allergen for desensitization and/or tolerance induction of allergic patients and for treatment and prophylaxis of allergy. More specifically, it relates to the administration of an allergen and a local vasoconstrictor through the intradermal route to enable a slow release of allergen and lower side effects of therapy.

An immunogenic product including at least one immunoglobulin or fragment thereof conjugated with a carrier protein, wherein the at least one immunoglobulin is IgE and preferably wherein the IgE fragment includes the IgE Cε3 domain, and wherein the carrier protein is preferably CRM.sub.197. Also the use of this immunogenic product for treating inflammatory disorders, and in particular allergic disorders.

Provided is herein are extracellular vesicles (EVs) comprising a lipid bilayer comprising one or more immunosuppressive molecules. Also provided herein are methods to induce tolerance to a therapeutic agent such as AAV, using the EVs described herein.

The present disclosure provides T-cell modulatory multimeric polypeptides (TMMPs) comprising a type 1 diabetes (T1D)-associated peptide epitope, MHC class II polypeptides, and one or more immunomodulatory polypeptides. A TMMP of the present disclosure is useful for modulating activity of a T cell. Thus, the present disclosure provides compositions and methods for modulating the activity of T cells, as well as compositions and methods for treating persons who have T1D.

Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.

The present invention provides compositions comprising tolerizing immune modified particles (TIMPs) and methods for using and making said TIMPs. In particular, carrier polymer is covalently conjugated with antigenic peptide before particle formation, which allows for exquisite control of particle size and antigen encapsulation (e.g., for use in eliciting induction of immunological tolerance).

The present disclosure relates to engineered IgG Fc constructs and uses thereof.

The present invention provides compositions comprising peptide-coupled biodegradable poly(lactide-co-glycolide) (PLG) particles. In particular, PLG particles are surface-functionalized to allow for coupling of peptide molecules to the surface of the particles (e.g., for use in eliciting induction of immunological tolerance).